News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,924 Results
Type
Article (40018)
Company Profile (250)
Press Release (664655)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204281)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16250)
Job Trends (14887)
News (345506)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1445)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2870)
Cardiovascular disease (213)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66860)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2624)
CRISPR (56)
C-suite (329)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (127)
Earnings (87461)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113748)
Executive appointments (845)
FDA (17907)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (375)
GLP-1 (783)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (493)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (90)
Medical device (13465)
Medtech (13470)
Mergers & acquisitions (19583)
Metabolic disorders (849)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2122)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57690)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29450)
Phase III (21920)
Pipeline (1637)
Policy (200)
Postmarket research (2563)
Preclinical (8871)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (89)
Last 7 days (350)
Last 30 days (1830)
Last 365 days (31170)
2025 (16820)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38212)
Australia (6232)
California (7444)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82112)
Florida (1119)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (638)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5531)
Michigan (246)
Minnesota (451)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2080)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3279)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2785)
Tennessee (126)
Texas (1127)
United States (27586)
Utah (220)
Virginia (186)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,924 Results for "duchesnay inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Duchesnay Pharmaceutical Group creates Advisory Board to help guide the Group’s growth and success
April 16, 2025
·
5 min read
Duchesnay Inc. is seeking Health Canada approval for a segesterone acetate/ethinyl estradiol contraceptive vaginal system, a new option for women
Duchesnay Inc., member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, has recently filed a New Drug Submission (NDS) to Health Canada for its segesterone acetate / ethinyl estradiol slow-release vaginal system developed for contraception control.
November 30, 2023
·
5 min read
Press Releases
Duchesnay Pharmaceutical Group wins 2024 Life Sciences Innovation Award from ADRIQ, the Association for the Development of Research and Innovation of Quebec
November 22, 2024
·
5 min read
Press Releases
Duchesnay Pharmaceutical Group celebrates expansion of its treatment portfolio for nausea and vomiting of pregnancy to 40 countries around the world
October 10, 2024
·
3 min read
Duchesnay announces the launch of Vablys® (dequalinium chloride vaginal tablets), an antiseptic and anti-infective treatment for bacterial vaginosis
Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys ® (dequalinium chloride vaginal tablets).
June 21, 2022
·
4 min read
Press Releases
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Slynd® (drospirenone), a new progestin-only contraceptive pill from Duchesnay which offers a 24-hour safe window for a missed pill
A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.
May 17, 2022
·
4 min read
Press Releases
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 15, 2025
·
13 min read
Press Releases
CoRegen, Inc. Closes More Than $93 Million Financing
July 10, 2025
·
3 min read
1 of 70,493
Next
